Cancer research in India: national priorities, global results

详细信息    查看全文

• 作者：Prof Richard Sullivan ; MD^a ; ^{richard.sullivan@kcl.ac.uk" class="auth_mail} ; Prof Rajendra A Badwe ; MS^b ; Prof Goura K Rath ; MD^c ; Prof C S Pramesh ; MS^b ; Prof V Shanta ; MD^e ; Prof Raghunadharao Digumarti ; MD^f ; Anil D'Cruz ; MS^b ; Prof Suresh C Sharma ; MD^g ; Prof Lokesh Viswanath ; MD^h ; Prof Arun Shet ; MDⁱ ; Prof Manavalan Vijayakumar ; MS^h ; Grant Lewison ; PhD^a ; Prof Mammen Chandy ; MD^b ; Priyadarshini Kulkarni ; MD^d ; M R Bardia ; MD^j ; Prof Shaleen Kumar ; MD^k ; Prof Rajiv Sarin ; MD^b ; Prof Paul Sebastian ; MS^l ; Preet K Dhillon ; PhD^m ; Preetha Rajaraman ; PhDⁿ ; Prof Edward L Trimble ; MD^o ; Ajay Aggarwal ; MD^a ; D K Vijaykumar ; MD^p ; Prof Arnie D Purushotham ; MD^a
• 刊名：Lancet Oncology
• 出版年：May 2014
• 年：2014
• 卷：15
• 期：6
• 页码：e213-e222
• 全文大小：281 K

文摘

Over the past 20 years, cancer research in India has grown in size and impact. Clinicians, scientists, and government and state policy makers in India have championed cancer research, from studies to achieve low-tech, large-scale health outcomes to some of the most advanced areas of fundamental cancer science. In this paper, we frame public policy discussions about cancer with use of an in-depth analysis of research publications from India. Cancer research in India is a complex environment that needs to balance public policy across many competing agendas. We identify major needs across these environments such as those for increased research capacity and training and protected time for clinical researchers; for more support from states and enhanced collaborative funding programmes from government; for development of national infrastructures across a range of domains (ie, clinical trials, tissue banking, registries, etc); and for a streamlined and rational regulatory environment. We also discuss improvements that should be made to translate research into improvements in cancer outcomes and public health.